title: Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
abstract: Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia or myelodysplastic syndromes. Patients and Methods Patients age 18 to 65 years with HCT comorbidity index ≤ 4 and < 5% marrow myeloblasts pre-HCT were randomly assigned to receive MAC (n = 135) or RIC (n = 137) followed by HCT from HLA-matched related or unrelated donors. The primary end point was OS 18 months post-random assignment based on an intent-to-treat analysis. Secondary end points included relapse-free survival (RFS) and TRM. Results Planned enrollment was 356 patients; accrual ceased at 272 because of high relapse incidence with RIC versus MAC (48.3%; 95% CI, 39.6% to 56.4% and 13.5%; 95% CI, 8.3% to 19.8%, respectively; P < .001). At 18 months, OS for patients in the RIC arm was 67.7% (95% CI, 59.1% to 74.9%) versus 77.5% (95% CI, 69.4% to 83.7%) for those in the MAC arm (difference, 9.8%; 95% CI, -0.8% to 20.3%; P = .07). TRM with RIC was 4.4% (95% CI, 1.8% to 8.9%) versus 15.8% (95% CI, 10.2% to 22.5%) with MAC ( P = .002). RFS with RIC was 47.3% (95% CI, 38.7% to 55.4%) versus 67.8% (95% CI, 59.1% to 75%) with MAC ( P < .01). Conclusion OS was higher with MAC, but this was not statistically significant. RIC resulted in lower TRM but higher relapse rates compared with MAC, with a statistically significant advantage in RFS with MAC. These data support the use of MAC as the standard of care for fit patients with acute myeloid leukemia or myelodysplastic syndromes.
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Bart L
authors.initials: BL
authors.lastname: Scott
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Marcelo C
authors.initials: MC
authors.lastname: Pasquini
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Brent R
authors.initials: BR
authors.lastname: Logan
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Juan
authors.initials: J
authors.lastname: Wu
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Devine
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Erica D
authors.initials: ED
authors.lastname: Warlick
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Hugo F
authors.initials: HF
authors.lastname: Fernandez
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamadani
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Asad
authors.initials: A
authors.lastname: Bashey
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Geller
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Eric
authors.initials: E
authors.lastname: Leifer
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Le-Rademacher
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Mendizabal
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Mary M
authors.initials: MM
authors.lastname: Horowitz
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
authors.affiliation: Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
authors.forename: Mitchell E
authors.initials: ME
authors.lastname: Horwitz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage; D002423:Cause of Death; D016572:Cyclosporine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D012008:Recurrence; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014916:Whole-Body Irradiation; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine; D008558:Melphalan